What a clearer
media decision looks like.

Fictional audience: 1,000 core specialists in the launch footprint and 2,000 expansion clinicians in relevant referral roles, mutually exclusive in the planning list. List size is not reachable audience size; partner eligibility and cross-partner overlap still need verification.

Cost boundary: 100 units cover paid media only, including the Learning test placements. A separate invented 20 units cover data (5), measurement (4), production (8), and advisory fees (3): 120 units all-in. There is no dollar conversion. The workbook totals only the 100-unit allocation; it does not model these supplemental costs.

Invented buying constraints: Core placements require a 20-unit minimum; expansion requires 10; Learning requires 10. Until deduplicated delivery is evidenced, the brand owner caps core spend at 50 to manage concentration risk. Expansion content is assumed cleared for only part of the period, creating a 35-unit ceiling. These are fictional spending guardrails, not measured inventory capacity or frequency forecasts.

Content readiness: Assume a reviewed core overview and landing page are ready at launch. Expansion education clears in week three. Learning compares two cleared content routes using agreed engagement definitions. In real work, approval dates, trafficking, inventory and permitted data use must be confirmed before commitment.

No choice is optimized for outcomes. If actual costs, content or audience evidence differ, rebuild the feasible set before ranking expected value.

Learning is a test allocation across these segments, not a third audience or an additional audience count. Setting-based point-of-care inventory stays on hold until setting relevance, content fit and reporting can be evidenced.

Decision rule: A favorable cost cannot offset an unresolved permission or content gate. The brand lead owns audience and content decisions; analytics validates identity, overlap and reporting definitions; procurement owns commercial review. The execution owner receives the assumptions, allocation, cleared assets, partner gates and unresolved issues.

First review: Compare delivery to the agreed allocation, inspect qualified delivery where supported, and examine frequency and overlap where available. Keep aggregate or unknown delivery separately labeled. Revisit commitments when a gate fails. Exposure and engagement do not establish prescribing impact; any outcome study requires a separate design and authorized data.

Media-addressable: Awareness of the resource and discoverability of preparation content. Use relevant contextual placements and carefully reviewed search topics to connect people with the guide. Context or a search signal does not verify a diagnosis; do not label exposed people as confirmed patients or infer a caregiver relationship.

Audience evidence: Document signal provenance, inferred versus observed status, permitted use and platform restrictions before selection. This example does not require condition-based audience lists or sensitive-event retargeting. Partner relevance and data use remain approval gates.

Content and access: Assess preferred languages, literacy and health literacy through authorized research. Require plain language, reviewed translations, descriptive links, keyboard and screen-reader usability, readable contrast, captions for any video, and a printable low-bandwidth version. Test comprehension and task completion with appropriate participants; availability of a translation alone does not prove understanding.

Other owners: The content owner resolves unclear instructions; accessibility and language specialists validate usability. Patient-support or access teams handle affordability and service eligibility. Clinical and referral teams own diagnosis and referrals; service operators own appointment capacity. Media can make approved routes discoverable but cannot promise these barriers are resolved.

Before spend: The sponsor confirms the unbranded purpose and destination; medical, legal and regulatory reviewers approve the content and links. Privacy and data owners approve collection and reporting. Relevant safety teams define any required reporting process for responses. The execution owner validates assets, accessible versions, tracking and support-link availability. A later branded adaptation would need its own claim, fair-balance and destination review; this unbranded approval would not carry over.

Measure the intended action: Report delivered placements and available audience-relevance evidence separately from guide opens, save/print actions and voluntary usefulness feedback. Define unique versus total events, valid traffic and event denominators before launch. A print action is intent to prepare, not proof of a completed visit. Use only approved, minimized reporting; avoid collecting diagnoses or question text for media measurement.

At the agreed review: If people reach the page but cannot find or use the guide in usability checks, fix the destination before expanding spend. If approved measurement shows relevant visits and guide use while access checks pass, consider extending the test. Agree thresholds from the actual objective and evidence; none is invented here. If support capacity is unavailable, the service owner resolves it before promotion of that route resumes.

Outcome limit: Exposure, clicks and guide use do not demonstrate comprehension, adherence, prescribing, clinical benefit or improved health. Those questions require separate research, appropriate permissions and a design capable of supporting the claim.